Last updated on October 2017

International Multicenter Observational Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan


Brief description of study

The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment in the Russian Federation and in the Republic of Kazakhstan..

Detailed Study Description

The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat people who have hypertension. This study will look at the clinic systolic and diastolic blood pressure (SBP, DBP) in obese participants who will be prescribed with azilsartan medoxomil by physician. The study will enroll approximately 1916 patients. All participants will be asked to take azilsartan medoxomil as prescribed by their physician according to local SmPC. This multi-center trial will be conducted in the Russian Federation and the Republic of Kazakhstan. The overall duration of study for observation will be approximately 6 months. Participants will make multiple visits to the clinic as assigned by each physician according to their routine practice, in every 3 months.

Clinical Study Identifier: NCT02756819

Contact Investigators or Research Sites near you

Start Over

Takeda Study Registration Call Center

Penza Regional Clinical hospital named after N.N. Burdenko
Penza, Russian Federation
3.17miles
  Connect »

Takeda Study Registration Call Center

Regional clinical hospital named after N.N. Burdenko
Penza, Russian Federation
3.17miles
  Connect »